CRISPR Gene Editing: Can It Treat Humans Today, and What Comes Next?

What exactly is CRISPR gene editing?

Your DNA contains the instructions that help cells make proteins and perform thousands of tasks. Some inherited illnesses begin when an important gene contains a disease-causing change. Gene editing aims to alter the DNA itself, potentially providing a lasting biological effect rather than repeatedly treating symptoms.

The original CRISPR–Cas9 system uses a guide RNA to direct a protein to a specific DNA sequence, where it cuts both strands. As the cell repairs the cut, scientists can disrupt a gene or, under some conditions, guide a desired change. The system is powerful, but the editing result is not always perfectly predictable. [3][16]

Importantly, gene editing is not the same as all gene therapy. Some FDA-approved gene therapies add a working gene using a viral delivery system rather than directly modifying a patient's existing DNA sequence. For instance, Lyfgenia, another sickle cell treatment approved in 2023, uses a lentiviral vector; it is not CRISPR editing. [3]

What are CRISPR, base editing and prime editing?

Two delivery strategies also matter: ex vivo means cells are removed, edited in a lab, checked and returned to the patient. In vivo means editing ingredients are delivered into the body to reach cells directly. The latter might eventually avoid some lengthy cell-manufacturing steps, but safely reaching the correct tissue remains a major challenge. [14][19]

Can gene editing already be used to treat human patients?

Yes. The FDA approved Casgevy (exagamglogene autotemcel) for sickle cell disease with recurrent vaso-occlusive crises on December 8, 2023, and for transfusion-dependent beta-thalassemia on January 16, 2024. On July 1, 2026, the agency expanded both indications from ages 12 and older to ages two and older. Approval does not mean every patient with either diagnosis is a suitable candidate. [1][2][3]

Casgevy is not currently an approved treatment for Alzheimer's disease, Parkinson's disease, ordinary aging, diabetes, most cancers or inherited conditions in general. A gene-editing strategy may work in research for one condition without proving it safe or effective for another.

What actually happens when someone receives Casgevy?

1. Evaluation at a specialized center. A hematology and transplantation team examines eligibility, other health conditions, fertility considerations, insurance and support needs.
2. Collection of blood-forming stem cells. The patient's own cells are collected and shipped for editing.
3. CRISPR editing outside the body. In a manufacturing laboratory, CRISPR modifies a regulatory region associated with the gene BCL11A. This helps the resulting red blood cells produce more fetal hemoglobin, which can compensate for defective adult hemoglobin.
4. Intensive preparatory chemotherapy. Before the edited cells return, the patient receives myeloablative conditioning, which creates room for them in the bone marrow and entails serious risks.
5. Infusion and recovery. The edited cells are given back, followed by hospitalization, recovery, infection monitoring and long-term medical follow-up.

The initial FDA sickle cell disease analysis reported that 29 of 31 evaluable patients (93.5%) experienced no severe vaso-occlusive crises for at least 12 consecutive months during the study's follow-up period. That is an important result, but it is not a guarantee that every treated person will have the same outcome or that long-term safety is fully understood. [3]

What are the newest breakthroughs?

A personalized base-editing treatment for one infant

In May 2025, NIH-supported researchers reported a remarkable one-person treatment for a baby with carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare disease that prevents the body from safely processing nitrogen. Investigators designed a customized base editor to target the child's specific mutation and used lipid nanoparticles to deliver it to the liver. Early follow-up showed encouraging improvements, including greater tolerance of dietary protein. A February 2026 children's-hospital update reported continued developmental progress. [8][9]

This is not an FDA-approved, commercially available treatment. The FDA permitted the individualized experimental use. Other patients would require their own specialist evaluation, manufacturing, safety testing and regulatory oversight.

First reported prime editing directly inside a person

On October 22, 2026, Nature reported that the first participant had received an in vivo prime-editing treatment in a trial for Wilson's disease, a condition in which copper accumulates in the body because of problems involving the ATP7B gene. Prime editing may allow small DNA changes to be corrected without the same type of double-strand break used by conventional Cas9. Researchers have not yet reported clinical outcome data for this first participant, so neither effectiveness nor durability is established. [10]

An in-body CRISPR treatment is approaching an FDA decision

A separate experimental CRISPR–Cas9 medicine, lonvoguran ziclumeran (lonvo-z), is being studied for hereditary angioedema, a genetic condition associated with potentially dangerous swelling episodes. In an 80-person randomized phase 3 trial, investigators reported an 87% lower monthly attack rate versus placebo during the prespecified follow-up period. That result reflects a trial population, not a promise for an individual patient. [11][12]

In September 2026, the manufacturer announced that the FDA accepted its application for priority review, with a target action date of March 10, 2027. FDA acceptance and priority review do not mean approval; the agency can approve, delay or decline an application. The price is not yet established as an approved marketed product. [13]

FDA is developing rules for more personalized treatments

On October 27, 2026, the FDA published draft guidance for individualized genome-editing products. It addresses the prospect of a shared regulatory application covering a family of related treatments, each tailored to different genetic variants. This could eventually make uncommon, mutation-specific therapies easier to develop, but the guidance is not final and does not itself approve any medication. [15]

How much does CRISPR treatment cost?

A published drug price is only part of the expense. The full treatment process can involve specialized evaluations, stem-cell collection, a manufacturing period, high-dose chemotherapy, lengthy hospitalization, blood products, infection care, travel and fertility preservation. Bills and reimbursements vary, so there is no honest one-number estimate of every patient's total cost. [4][6]

Will insurance, Medicare or Medicaid cover the treatment?

Some insurers and Medicaid programs cover medically necessary cell and gene therapies when eligibility and authorization requirements are met, but coverage is not automatic. Medicare coverage is especially dependent on the patient's situation and applicable benefits; Casgevy should not be assumed covered merely because the FDA approved it.

The federal Cell and Gene Therapy Access Model supports outcomes-based Medicaid arrangements for selected sickle cell gene therapies. Participating states and manufacturers help coordinate treatment and related services; eligibility rules apply. Illinois began participating January 1, 2026. Families should request a written benefits assessment from the specialized treatment center and health plan before making financial decisions. [6][7]

Experimental therapies are generally accessed through a regulated clinical trial or a specific regulatory pathway—not by purchasing a CRISPR kit, supplement or gene-editing service online.

What are the risks and what remains unknown?

Permanent DNA changes require particular caution. An editor can sometimes affect unintended DNA locations (“off-target” changes), and even editing at the intended site can produce unplanned outcomes. Researchers examine genetic rearrangements, immune reactions, tissue delivery, and long-term effects, including potential cancer risks. FDA guidance specifically addresses methods to evaluate unwanted edits. [4][16]

For Casgevy, much of the immediate medical burden also comes from myeloablative chemotherapy and stem-cell transplantation: infection risk, low blood counts, mucosal injury, prolonged recovery and potential infertility. Specialist centers must discuss fertility-preservation options beforehand. Long-term follow-up remains important because the modified stem cells may persist for decades. [3][4][6]

For in-body methods, additional unknowns include how accurately the editor reaches the desired organs, how much editing occurs, how long the editing machinery remains active, and what happens in other tissues. A highly precise editing enzyme is not a guarantee of precise delivery.

Is editing a patient's DNA the same as editing future generations?

No. Today's approved treatments edit somatic cells, such as a patient's blood-forming stem cells; the goal is to treat that patient, not to pass edits to their children. Heritable or germline editing would alter eggs, sperm or embryos so changes could pass to future generations. It raises distinct ethical and safety concerns and has no FDA-approved reproductive clinical use in the United States. NIH also does not fund human embryo gene-editing research. [17][18]

Will CRISPR eventually treat many more diseases—or even aging?

The most credible near-term prospects concern disorders with a well-defined genetic cause, an accessible target tissue and a measurable clinical outcome. Researchers are studying therapies for rare metabolic illnesses, blood disorders, hereditary angioedema, immune diseases and some forms of cancer. Base editing and prime editing could expand the number of genetic changes that scientists can address. [14]

Another critical direction is delivery: researchers are refining lipid nanoparticles, tissue-targeting methods and less invasive treatment strategies. Artificial intelligence is also being applied to design better editors and forecast unintended changes. These advances may eventually make more treatments feasible and possibly reduce manufacturing complexity, but neither lower prices nor broad clinical effectiveness is guaranteed. [19]

What about Alzheimer's disease, Parkinson's disease and longevity? These conditions often involve many biological pathways rather than a single easily corrected mutation. Gene editing is being investigated in laboratories, but there is no FDA-approved CRISPR treatment for Alzheimer's, Parkinson's or ordinary human aging. Headlines about editing aging-associated genes in cells or animals should not be confused with demonstrated life-extension therapies in humans.

The real breakthrough is already substantial: researchers now have evidence that editing a person's own DNA can help treat certain serious diseases. The open questions are how broadly, safely, durably and affordably that success can be reproduced.

What should families ask a gene-therapy specialist?

1. Is this specific therapy FDA-approved for this diagnosis and age? An approved medicine is different from an ongoing clinical trial.
2. How strong is the evidence? Ask how many people were treated, how long they were followed and what improved.
3. What are the near-term and long-term risks? Include chemotherapy, fertility effects, genetic changes and ongoing monitoring.
4. Is the patient eligible for treatment at an authorized center? Ask what health conditions might affect eligibility.
5. What is the complete projected cost? Request a written insurance review that covers the product, hospital stay, related services and travel.
6. What support will be required during recovery? Discuss transportation, caregiver responsibilities and the difference between clinical nursing and non-medical home assistance.